Skip to main content


Fig. 5 | Cell & Bioscience

Fig. 5

From: Ouabain prevents pathological cardiac hypertrophy and heart failure through activation of phosphoinositide 3-kinase α in mouse

Fig. 5

Effects of ouabain on TAC-induced chamber dilation in Con and p85-KO mice. Experiments were done as described in “Methods”. Left ventricular chamber size was monitored by echocardiography before and after 8 weeks of the TAC or sham surgery. Ouabain was infused subcutaneously (50 μg/kg/day) by ALZET osmotic pumps for continuous dosing for the first 4 weeks. a End diastolic dimension (EDD); b end systolic dimension (ESD). n = 6 ~ 7, *P < 0.05 vs. Sham; # P < 0.05 vs. TAC

Back to article page